What is Posmeal MD (Voglibose) used for?

Posmeal MD (Voglibose) belongs to the group of oral hypoglycemic medications, classified as competitive alpha glucosidase inhibitors. Alpha glucosidase enzymes help break down disaccharides, oligosaccharides, and polysaccharides. When alpha glucosidase enzymes are blocked, the processes of breaking down complex carbohydrates and absorbing glucose are slowed down. As a result, the blood glucose level after a meal goes down as well. At the same time, Posmeal MD (Voglibose) does not affect beta glucosidase enzymes.

Once administered, Posmeal MD (Voglibose) is slowly absorbed and quickly metabolized and eliminated from the body with feces. No Posmeal MD (Voglibose) metabolites have been registered in blood and urine.

How should I use Posmeal MD (Voglibose)?

It should be noted that in order to avoid adverse events, for many patients it is recommended to start the treatment with one 0.2mg tablet of Posmeal MD (Voglibose) taken three times daily. The medication should be administered immediately before every meal. The dose may be later increased up to 0.3mg taken three times daily if the initial standard dosage did not produce the expected therapeutic effects.

What are the side effects of Posmeal MD (Voglibose)?

Side effects of the medication are the adverse events. They are the part of the pharmacological activity and occur when the medication is used in therapeutic doses. Normally, most side effects are mild, well tolerated by patients, and subside after the medication has been discontinued or the dose has been reduced. However, some side effects may be severe and even life threatening.

If you experience any side effects associated with Posmeal MD (Voglibose), make sure to contact your physician immediately. Potential side effects may include:

• Metabolic disorders: hypoglycaemia.
• Gastro-intestinal tract: bloating, flatulence, diarrhea, bowel obstruction.
• Hepatobiliary system: fulminant hepatitis, severely impaired liver function, elevated liver transaminase levels (aspartate aminotransferase, alanine aminotransferase), jaundice.

Please Note

Posmeal MD (Voglibose) administration should be limited in patients who have been conclusively diagnosed with diabetes or glucose tolerance disorder.

Patients with diabetes who have been prescribed a diet and/or physical exercise should only receive Posmeal MD (Voglibose) when their postprandial blood glucose level within 2 hours after a meal reaches or exceeds 11.1 mmol/L.

Patients with diabetes who have been prescribed a diet, physical exercise, oral hypoglycemic medications or insulin should only receive Posmeal MD (Voglibose) when their blood glucose level before a meal reaches or exceeds 7.77 mmol/L.

In the course of the treatment with Posmeal MD (Voglibose), it is necessary to monitor the patient's condition and constantly regulate the blood glucose level. Moreover, to achieve the desired therapeutic effect the medication has to be taken continuously without breaks.

If after 2-3 months of continuous administration, both as single drug therapy and in combination with other drugs, the achieved hypoglycemic results are still not satisfactory (postprandial blood glucose level within 2 hours after a meal reaches or exceeds 11.1 mmol/L), the treatment regimen has to be adjusted accordingly.

If after Posmeal MD (Voglibose) administration, both as single drug therapy and in combination with other drugs, the achieved hypoglycemic results are satisfactory (postprandial blood glucose level within 2 hours after a meal is less than or equals 8.88 mmol/L), the treatment has to be discontinued, and further progress of the disease has to be monitored.

If you're intolerant to some sugars, it is necessary to consult your physician before starting the treatment, because the medication contains lactose.